CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...
Pfizer said Tuesday morning that final trial studies still show its experimental COVID-19 pill significantly reduced the risk of hospitalization or death linked to the virus by 89%. The company also ...
NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results